Reuters File Photo: The AstraZeneca logo is seen outside the North American headquarters in Wilmington, Delaware, USA, March 22, 2021.
(Reuters) – A late-stage study of the experimental COVID-19 antibody drug cocktail of Estrogenica has succeeded in reducing serious illness or death in patients who were not hospitalized, the British drugmaker said on Monday.
The drug AZD7442 reduces the risk of developing severe Covid-1 or death by 50% in patients who have been symptomatic for seven days or less, which has met the main goal of the trial.
“Early intervention with our antibodies can significantly reduce the progression of serious disease, with protection over a period of more than six months,” said Man Pangalos, executive vice president of biopharmaceuticals R&D at AstraZeneca (Nasdaq :).
The agency will discuss the data with health authorities, it added, without giving details.
AstraZeneca is also developing a drug cocktail as a therapy to protect people who do not have strong enough immunity against the Covid-1 vaccine. It last week requested urgent approval from U.S. regulators for use as a preventative drug.
Fusion Media Or anyone involved with Fusion Media will not assume any liability for loss or damage as a result of relying on the information contained in this website, including data, quotes, charts and buy / sell signals. Please be fully aware of the risks and costs associated with trading in the financial markets, this is one of the potential risky investment forms.